News|Articles|July 2, 2018

In the Lab eNewsletter

  • Pharmaceutical Technology\'s In the Lab eNewsletter-07-03-2018
  • Volume 13
  • Issue 7

New Orbitrap ID-X Tribrid Mass Spectrometer Enhances Small-Molecule Characterization

Thermo Fisher Scientific’s mass spectrometer combines mass-analyzer technology with an intelligent data acquisition strategy.

Thermo Fisher Scientific’s Orbitrap ID-X Tribrid Mass Spectrometer combines mass-analyzer technology dedicated for small-molecule analysis with the company’s AcquireX intelligent MSⁿ data acquisition strategy, which allows the collection of more meaningful data. The system’s intuitive, automated workflow accelerates results by capturing more low-abundance analytes and leveraging streamlined data analysis and mass-spectral prediction tools, according to the company.

The technology helps dissipate bottlenecks by:

  • enabling scientists to push the limits of complex small-molecule challenges using Thermo Scientific Tribrid architecture.

  • increasing profiling efficiency and selectivity using intelligent AcquireX data acquisition, allowing for more meaningful data collection.

  • extracting meaningful MSⁿ data faster with high confidence using an integrated set of data analysis tools.

  • demystifying unknown variables using novel spectral prediction tools and processing routines to interpret MSⁿ data.

Source: Thermo Fisher Scientific


Related to this article

Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.